Pharmaceutical companies list the number of research products, 1 Chinese company on the list

"
Pharmaceutical Network Industry Dynamic" For pharmaceutical companies, research and development is the source of power, the number of products in research is the specific performance of research and development capabilitiesAccording to the Pharmaprojects database, there were 17,737 new drugs in the world as of January 2020To further analyze the number of drugs studied at the corporate level, it ranks the top 25 companies in the number of research productsspecifically, the top three pharmaceutical companies on the list are Novartis, Takeda and BMS, with 222, 198 and 189 drugs in the researchFor the fourth year in a row, Novartis has ranked first in the world in the number of drugs studiedAlthough it has only slightly increased in the size of its research drugs, its advantage sharply remains clear compared to that of The Second-ranked Takedataked Takeda Pharmaceuticals to remain ranked 2nd in the world in the number of drugs studied in 2020, thanks to the completion of taked-up of Shire in 2018, which increased from 164 to 211Although the number of self-research drugs declined last year due to structural adjustment and variety integration, Takeda Pharmaceuticals still occupies the runner-up spot by relying on the cumulative quantitative advantagethe top three companies, BMS has made big progress, with its ranking rapidly soaring from 11th in 2019 to No3Like Takeda, the industry believes this is largely due to BMS's $74 billion acquisition of Celgene in 2019, which has increased the number of drugs it is working on from 110 in 2019 to 189notable, in this list, Hong Kong-based Li's big pharmacy, with 74 products in the research ranked 21st, is the first Chinese company to enter the top 25It is understood that Li's large pharmaceutical factory is a family-owned enterprise with concentrated equity, its business model is a typical independent research and development of the company1997, the Group launched the first independent research and development of products injection with the reduction of fiber-reducing enzyme Defibrase, after which with the injection of low molecular weight heparin calcium (Li Meiqing), recombinant interferon alpha 2b gel (Yu Jingan) and other independent research and development products have been listed in the domestic market, Li's large pharmaceutical factory completed the initial stage of technical accumulation In 2002, the company was listed in the Hong Kong Venture Seup, and then transferred to the main board in May 2010 At present, Li's large pharmaceutical company sells a total of six core products, self-research products have low molecular heparin preparation injection with low molecular amount of heparin calcium (Limeiqing), dermatology department / gynaecological recombinant human interferon alpha-2b gel (Yu Jingan), treatment to reduce bleeding drugs Snake venom hyaluo injection (quick music), the introduction of products are the treatment of iron deficiency anemia drug protein iron palsy oral solution (Fitly), the treatment of cardiovascular disease drug zokanitin injection (can benefit), the treatment of hypertension drug lecatiparflat tablets (rening flat) Six major products accounted for 93% of the company's sales revenue, of which Yu Jing'an ® accounted for 10% of the company's main business revenue.